Close Menu

NEW YORK – Agilent Technologies said on Wednesday that it has signed an agreement with San Francisco-based startup InterVenn to investigate glycoproteomic biomarkers for diseases common in Southeast Asia, such as cancer.

The team plans to begin development work at InterVenn Malaysia's laboratory at Technology Park Malaysia in Kuala Lumpur.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.